| Entry |
|
|---|
| Name |
Amfetamine (INN);
Amphetamine;
Adzenys (TN);
Dyanavel (TN) |
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C9H13N
|
|---|
| Exact mass |
135.1048
|
|---|
| Mol weight |
135.21
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Remark |
| Product (DG00966): | D07445<US> D02074<US> |
|
|---|
| Efficacy |
Stimulant (central) |
|---|
| Disease |
Attention deficit hyperactivity disorder [DS: H01895] |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07234 | Neurotransmitter transporter inhibitors |
|
|---|
| Other map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N06 PSYCHOANALEPTICS
N06B PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06BA Centrally acting sympathomimetics
N06BA01 Amfetamine
D07445 Amfetamine (INN) <US>
USP drug classification [BR:br08302]
Central Nervous System Agents
Attention Deficit Hyperactivity Disorder Agents, Amphetamines
Amphetamine
D07445 Amfetamine (INN)
Target-based classification of drugs [BR:br08310]
Transporters
Solute carrier family
SLC6
SLC6A2 (NAT1)
D07445 Amfetamine (INN) <US>
SLC6A3 (DAT1)
D07445 Amfetamine (INN) <US>
SLC18
SLC18A2 (VMAT2)
D07445 Amfetamine (INN) <US>
Prodrugs [br08324.html]
D07445
Narcotics and psychotropics in Japan [br08308.html]
Stimulants by Control Act Article 2 Appended Table and Cabinet Order
D07445
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 10
1 C8y C 18.0426 -15.4812
2 C8x C 16.8566 -14.7835
3 C8x C 18.0426 -16.8766
4 C1b C 19.2287 -14.7835
5 C8x C 15.6008 -15.4812
6 C8x C 16.8566 -17.5742
7 C1c C 20.4845 -15.4812
8 C8x C 15.6008 -16.8766
9 N1a N 21.6705 -14.7835
10 C1a C 20.4845 -16.8766
BOND 10
1 1 2 2
2 1 3 1
3 1 4 1
4 2 5 1
5 3 6 2
6 4 7 1
7 5 8 2
8 7 9 1
9 7 10 1
10 6 8 1
|
|---|
